Abstract
Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should he discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.
| Original language | English |
|---|---|
| Pages (from-to) | 979-981 |
| Number of pages | 3 |
| Journal | Haematologica |
| Volume | 90 |
| Issue number | 7 |
| Publication status | Published - Jul 2005 |
Fingerprint
Keywords
- Chronic myeloid leukemia
- Imatinib
- Therapy discontinuation
ASJC Scopus subject areas
- Hematology
Cite this
Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. / Merante, Serena; Orlandi, Ester; Bernasconi, Paolo; Calatroni, Silvia; Boni, Marina; Lazzarino, Mario.
In: Haematologica, Vol. 90, No. 7, 07.2005, p. 979-981.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation
AU - Merante, Serena
AU - Orlandi, Ester
AU - Bernasconi, Paolo
AU - Calatroni, Silvia
AU - Boni, Marina
AU - Lazzarino, Mario
PY - 2005/7
Y1 - 2005/7
N2 - Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should he discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.
AB - Imatinib mesylate (IM) therapy is effective in patients with chronic myeloid leukemia (CML). However, whether it should he discontinued in patients who achieve sustained molecular response is debated. We describe 4 patients with undetectable levels of BCR-ABL transcripts in whom IM therapy was discontinued. Two patients relapsed after 7 and 10 months and promptly responded after restarting therapy; 2 patients are off therapy at the last follow-up visit after 14 and 15 months and are still in complete molecular remission.
KW - Chronic myeloid leukemia
KW - Imatinib
KW - Therapy discontinuation
UR - http://www.scopus.com/inward/record.url?scp=22544459376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22544459376&partnerID=8YFLogxK
M3 - Article
C2 - 15996937
AN - SCOPUS:22544459376
VL - 90
SP - 979
EP - 981
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 7
ER -